4D Molecular Therapeutics, a late-stage biotech company, announced it will present and hold one-on-one meetings at the BofA Securities Healthcare Conference on May 13 and the RBC Global Healthcare Conference on May 19, 2026. The company is advancing treatments for retinal diseases and cystic fibrosis, with its lead product 4D-150 in Phase 3 trials for wet age-related macular degeneration. These presentations aim to update investors on progress and future milestones. Archived webcasts will be available for one year on the company's investor website.
Cortea secured €12 million in funding led by Dawn Capital to develop AI-powered Audit Quality Agents that review audit reports and financial statements, identifying errors and inconsistencies before sign-off. These tools help audit firms improve qual...
Cortea secured €12 million in seed funding led by Dawn Capital to develop AI tools that enhance audit quality without compromising accuracy. Their Audit Quality Agents review audit reports and financial statements to detect inconsistencies and errors...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign featuring a series of vibrant summer events including the 50th Sun Life Hong Kong International Dragon Boat Festival, Pixar Summer Fest, and a major football event with top Euro...
Hong Kong Tourism Board has launched the "Hong Kong Summer Fun" campaign, featuring festivals, family attractions, sports events, and exclusive summer deals valid until August 31. Highlights include the 50th Sun Life Hong Kong International Dragon Bo...
XTransfer has been recognized for the second consecutive year in FXC Intelligence’s 2026 Top 100 Cross-Border Payments Companies list, highlighting its role in advancing global B2B payment solutions. The company, serving over 890,000 enterprises in 2...
